| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/16/2023 |
SC 13D/A
| GSK plc reports a 10.9% stake in Haleon plc |
| 02/14/2023 |
SC 13G/A
| DODGE & COX reports a 5.5% stake in GSK plc |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/30/2023 |
SC 13G
| GSK PLC reports a 11% stake in Wave Life Sciences Ltd. |
| 01/20/2023 |
SC 13D/A
| GSK PLC reports a 12.2% stake in 23ANDME HOLDING CO. |
| 01/20/2023 |
SC 13D/A
| GSK PLC reports a 17.8% stake in SPERO THERAPEUTICS, INC. |
| 11/14/2022 |
SC 13D/A
| GSK PLC reports a 20% stake in SPERO THERAPEUTICS, INC. |
| 11/04/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 09/20/2022 |
SC 13D/A
| GSK PLC reports a 0% stake in THERAVANCE BIOPHARMA, INC. |
| 08/03/2022 |
SC 13D/A
| GSK PLC reports a 12.7% stake in THERAVANCE BIOPHARMA, INC. |
| 07/27/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/13/2022 |
SC 13D/A
| GSK PLC reports a 6.8% stake in Nkarta, Inc. |
| 02/14/2022 |
SC 13G
| DODGE & COX reports a 5.9% stake in GlaxoSmithKline plc |
| 02/10/2022 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 9.9% stake in Genocea Biosciences, Inc. |
| 02/10/2022 |
SC 13G
| GLAXOSMITHKLINE PLC reports a 12.6% stake in LYELL IMMUNOPHARMA, INC. |
| 02/10/2022 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 3.9% stake in * F-Star Therapeutics, Inc. |
| 02/10/2022 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 13.1% stake in THERAVANCE BIOPHARMA, INC. |
| 02/10/2022 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 6.5% stake in VIR BIOTECHNOLOGY, INC. |
| 02/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/27/2021 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 4.5% stake in * Fulcrum Therapeutics, Inc. |
| 09/16/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 5.4% stake in SPERO THERAPEUTICS, INC. |
| 09/16/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 6% stake in BICYCLE THERAPEUTICS PLC |
| 07/12/2021 |
SC 13G
| GLAXOSMITHKLINE PLC reports a 5% stake in CVRx, Inc. |
| 05/25/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 0% stake in INNOVIVA, INC. |
| 04/16/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC has filed a Schedule 13D for BICYCLE THERAPEUTICS PLC |
| 04/08/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 0% stake in Pandion Therapeutics, Inc. |
| 02/12/2021 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 31.6% stake in INNOVIVA, INC. |
| 02/12/2021 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 9.9% stake in Genocea Biosciences, Inc. |
| 02/12/2021 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 3.4% stake in Progyny, Inc. |
| 01/29/2021 |
SC 13G/A
| BlackRock Inc. reports a 7.5% stake in GLAXOSMITHKLINE PLC |
| 12/07/2020 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 6.4% stake in SPERO THERAPEUTICS, INC. |
| 12/07/2020 |
SC 13D/A
| GLAXOSMITHKLINE PLC reports a 8.9% stake in BICYCLE THERAPEUTICS PLC |
|